RNF183 and non-small cell lung carcinoma: In NSCLC, FATE1 expression alone did notportend poor survival; however, we observed that patients with tumoursexpressing elevated FATE1 and RNF183 were at higher risk for poor survival(HR=2.53; P=0.0007; Cox Regression) as comparedwith those patients with one or neither expressed (Fig.3k).